Threshold Pharmaceuticals, Inc. Securities Litigation
On or around 09/14/2017 (Other)
Filing Date: June 20, 2017
According to the Complaint, on March 17, 2017, Molecular Templates, Inc., (“Molecular”) and the Company announced that they had entered into an Agreement and Plan of Merger (“Merger Agreement”) pursuant to which Trojan Merger Sub, Inc. (“Merger Sub”), a wholly owned subsidiary of Threshold, will merge with and into Molecular, with Molecular surviving as a wholly owned subsidiary of Threshold in an all-stock transaction (the “Proposed Transaction”).
The Complaint alleges on May 15, 2017, Defendants issued materially incomplete and misleading disclosures in the Form S-4 Registration Statement (the “Registration Statement”) filed with the United States Securities and Exchange Commission (“SEC”) in connection with the Proposed Transaction. The Registration Statement is deficient and misleading in that it fails to provide adequate disclosures of all material information related to the Proposed Transaction.
This case was voluntarily dismissed on August 23, 2017.
Company & Securities Information
Defendant: Threshold Pharmaceuticals, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: THLD
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Victor Pariso, et al. v. Threshold Pharmaceuticals, Inc., et al.
COURT: N.D. California
DOCKET #: 17-CV-03557
JUDGE: Hon. William Alsup
DATE FILED: 06/20/2017
CLASS PERIOD START: 03/17/2017
CLASS PERIOD END: 06/20/2017
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Levi & Korsinsky (San Francisco) 44 Montgomery Street, Suite 650, Levi & Korsinsky (San Francisco), CA 94104 (415) 291-2420 (415) 484-1294 ·
First Identified Complaint (FIC) Filings:
Class Action Complaint for Violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934
Stipulation Of Dismissal and [Proposed] Order
Order Denying Stipulation
Second Stipulation Of Dismissal and [Proposed] Order
Order Granting Stipulation as Modified
U.S. District Court Civil Docket
—Reference Complaint Complaint Related Data is not available
Related District Court Filings
—Related District Court Filings Data is not available